Neurocrine Biosciences
NBIX
#1370
Rank
A$23.33 B
Marketcap
A$234.03
Share price
0.84%
Change (1 day)
16.00%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): A$6.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$6.49. In 2024 the company made an earnings per share (EPS) of A$5.09 an increase over its 2023 EPS that were of A$3.82.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$6.6330.4%
2024A$5.0933.07%
2023A$3.8257.76%
2022A$2.4269.47%
2021A$1.43-78.21%
2020A$6.56990%
2019A$0.6081.82%
2018A$0.33-113.5%
2017A-$2.450.62%
2016A-$2.4457.28%
2015A-$1.5525.61%
2014A-$1.2318.84%
2013A-$1.04-1085.71%
2012A$0.11

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
A$0.04515-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.66-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
A-$91.80-1,515.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$30.88 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.03-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$2.59-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$2.57-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$3.05-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA